SMMT icon

Summit Therapeutics

20.32 USD
-0.28
1.36%
At close Mar 28, 4:00 PM EDT
Pre-market
19.99
-0.33
1.62%
1 day
-1.36%
5 days
2.06%
1 month
-1.79%
3 months
13.58%
6 months
-7.21%
Year to date
10.74%
1 year
390.82%
5 years
757.38%
10 years
65.88%
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

172% more first-time investments, than exits

New positions opened: 68 | Existing positions closed: 25

97% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 38

23% more funds holding

Funds holding: 164 [Q3] → 202 (+38) [Q4]

0.87% more ownership

Funds ownership: 11.68% [Q3] → 12.55% (+0.87%) [Q4]

11% less capital invested

Capital invested by funds: $1.85B [Q3] → $1.65B (-$199M) [Q4]

32% less call options, than puts

Call options by funds: $36.7M | Put options by funds: $53.9M

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$30
48%
upside
Avg. target
$36
79%
upside
High target
$44
117%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
Citigroup
Yigal Nochomovitz
19% 1-year accuracy
8 / 43 met price target
72%upside
$35
Buy
Upgraded
26 Mar 2025
Evercore ISI Group
Cory Kasimov
44% 1-year accuracy
7 / 16 met price target
48%upside
$30
Outperform
Initiated
12 Mar 2025
Goldman Sachs
Salveen Richter
29% 1-year accuracy
5 / 17 met price target
107%upside
$42
Buy
Initiated
28 Feb 2025
Citizens Capital Markets
Reni Benjamin
15% 1-year accuracy
6 / 41 met price target
57%upside
$32
Market Outperform
Reiterated
25 Feb 2025
HC Wainwright & Co.
Mitchell Kapoor
30% 1-year accuracy
55 / 181 met price target
117%upside
$44
Buy
Reiterated
25 Feb 2025

Financial journalist opinion

Based on 11 articles about SMMT published over the past 30 days

Positive
The Motley Fool
3 hours ago
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.
Building a retirement portfolio of $1 million or more is within reach for many Americans. The primary things you'll need are time and money to invest.
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.
Negative
The Motley Fool
4 days ago
Why Summit Therapeutics Stock Slipped Today
Summit Therapeutics (SMMT -2.25%) stock did better than a lot of other equities during an otherwise forgettable trading session on Wednesday. In contrast to other titles that fell notably, Summit more or less kept pace with the S&P 500 (^GSPC -1.12%), managing to dip by a relatively modest 2.25% in price.
Why Summit Therapeutics Stock Slipped Today
Positive
Proactive Investors
4 days ago
Summit Therapeutics upgraded ahead of lung cancer trial data readout
Summit Therapeutics PLC (NASDAQ:SMMT) has been upgraded to a ‘Buy' rating by Citi analysts who are optimistic about the company's HARMONi-2 trial of ivonescimab in non-small cell lung cancer. Citi also boosted its price target to $35.
Summit Therapeutics upgraded ahead of lung cancer trial data readout
Positive
Benzinga
6 days ago
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics
On Friday, Cantor Fitzgerald initiated coverage on Summit Therapeutics Inc. SMMT, citing shares as 67% undervalued.
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics
Positive
The Motley Fool
1 week ago
Is Summit Therapeutics a Millionaire Maker?
Multiple paths to immense wealth exist. A few lucky people win the lottery.
Is Summit Therapeutics a Millionaire Maker?
Neutral
Business Wire
1 week ago
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 147,500 shares of common stock. Awards were made to seven new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Commit.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Positive
The Motley Fool
1 week ago
This Unstoppable Biotech Stock Just Became an Even Better Buy
Last year, Summit Therapeutics (SMMT -1.24%) was one of the stars of the biotech industry. The company's shares soared following a significant clinical win.
This Unstoppable Biotech Stock Just Became an Even Better Buy
Neutral
Business Wire
1 week ago
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating Officer and Chief Financial Officer, effective immediately. Robert W. Duggan and Dr. Maky Zanganeh, Co-CEOs of Summit Therapeutics, stated, “Robert's extensive experience and proven track record in the oncology space make him an exceptional addition to our te.
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
Neutral
Business Wire
2 weeks ago
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 122,650 shares of common stock. Awards were made to 12 new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Positive
The Motley Fool
2 weeks ago
Why Summit Therapeutics Stock Was Winning This Week
A very bullish analyst move was the news generally responsible for Summit Therapeutics' (SMMT -3.62%) healthy mid-week stock price pop. That upward lift was largely holding as of Friday before market open, as according to data compiled by S&P Global Market Intelligence Summit's share price had risen by almost 8% week to date at that point.
Why Summit Therapeutics Stock Was Winning This Week
Charts implemented using Lightweight Charts™